NCT04019964 — Sidney Kimmel Comprehensive Cancer Center… cancer immunotherapy trial
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Registry record
| Registry ID | NCT04019964 ↗ |
|---|---|
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Collaborators | Bristol-Myers Squibb |
| Phase | Phase 2 |
| Status | Completed |
| Indication | Prostate Cancer, Recurrent Prostate Cancer |
| Enrollment | 8 participants |
| Start date | 2020-01-13 |
| Primary completion | 2025-04-23 |
| Last registry update | 15 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04019964), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
Related trials
FAQ
What phase is NCT04019964?
NCT04019964 (Nivolumab in Biochemically Recurrent dMMR Prostate Cancer) is registered on ClinicalTrials.gov as Phase 2, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Is NCT04019964 recruiting?
As of the 2026-05-15 registry update, NCT04019964 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04019964?
The lead sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Collaborators: Bristol-Myers Squibb.
What condition does NCT04019964 study?
The registered conditions are Prostate Cancer, Recurrent Prostate Cancer. Primary completion is listed as 2025-04-23.
Are results available for NCT04019964?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04019964.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.